Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Cash & Equivalents (2018 - 2025)

Dna X (SONM) has disclosed Cash & Equivalents for 8 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 76.41% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Sep 2025, down 76.41%, and an annual FY2024 reading of $5.3 million, up 5138.24% over the prior year.
  • Cash & Equivalents was $2.1 million for Q3 2025 at Dna X, up from $2.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $15.5 million in Q3 2022 and bottomed at $102000.0 in Q4 2023.
  • Average Cash & Equivalents over 5 years is $7.3 million, with a median of $7.9 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents plummeted 99.23% in 2023, then skyrocketed 5138.24% in 2024.
  • Year by year, Cash & Equivalents stood at $1.5 million in 2021, then skyrocketed by 780.87% to $13.2 million in 2022, then tumbled by 99.23% to $102000.0 in 2023, then surged by 5138.24% to $5.3 million in 2024, then crashed by 60.0% to $2.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for SONM at $2.1 million in Q3 2025, $2.0 million in Q2 2025, and $2.1 million in Q1 2025.